FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

773879000: Antineoplastic therapeutic role (role)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 31-Jan 2019. Module: SNOMED CT core module

Descriptions:

Id Description Lang Type Status Case? Module
3726859011 Antineoplastic therapeutic role en Synonym Active Entire term case insensitive SNOMED CT core module
3726860018 Antineoplastic therapeutic role (role) en Fully specified name Active Entire term case insensitive SNOMED CT core module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Antineoplastic therapeutic role Is a Therapeutic role true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Bortezomib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing daratumumab (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Daratumumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing oblimersen in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only oblimersen in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only oblimersen (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing oblimersen Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing sonidegib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only sonidegib (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ribociclib (as ribociclib succinate) 200 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ribociclib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only ribociclib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ribociclib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ribociclib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely sonidegib (as sonidegib phosphate) 200 milligram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pertuzumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only pertuzumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pertuzumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pertuzumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing procarbazine Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing procarbazine in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Procarbazine Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only procarbazine in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely procarbazine (as procarbazine hydrochloride) 50 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ponatinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ponatinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only ponatinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ponatinib (as ponatinib hydrochloride) 15 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely ponatinib (as ponatinib hydrochloride) 45 milligram/1 each conventional release oral tablet Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ponatinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing plicamycin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only plicamycin (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing plicamycin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only plicamycin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely plicamycin 500 microgram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely plicamycin 2.5 gram/1 vial powder for conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trametinib (as trametinib dimethyl sulfoxide) 500 microgram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely trametinib (as trametinib dimethyl sulfoxide) 2 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing trametinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing trametinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trametinib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only trametinib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pazopanib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Pazopanib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only pazopanib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pazopanib (as pazopanib hydrochloride) 200 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pazopanib (as pazopanib hydrochloride) 400 milligram/1 each conventional release oral tablet (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pazopanib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ofatumumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only ofatumumab in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Ofatumumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing ofatumumab Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only omacetaxine mepesuccinate in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only omacetaxine mepesuccinate (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing omacetaxine mepesuccinate Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing omacetaxine mepesuccinate in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Treosulfan Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only treosulfan in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only treosulfan in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing treosulfan in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing treosulfan in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing treosulfan Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely treosulfan 250 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely treosulfan 1 gram/1 vial powder for conventional release solution for injection Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely treosulfan 5 gram/1 vial powder for conventional release solution for injection Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Tivozanib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only tivozanib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing tivozanib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing tivozanib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely porfimer sodium 15 milligram/1 vial powder for conventional release solution for injection Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely porfimer sodium 75 milligram/1 vial powder for conventional release solution for injection Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing porfimer Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Porfimer Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only porfimer in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing porfimer in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pralatrexate in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only pralatrexate in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely pralatrexate 20 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only pralatrexate (medicinal product) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing pralatrexate Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Temoporfin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing temoporfin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only temoporfin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely temoporfin 4 milligram/1 milliliter conventional release solution for injection (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing temoporfin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing trabectedin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Trabectedin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only trabectedin in parenteral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing trabectedin Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing anagrelide Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only anagrelide in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely anagrelide (as anagrelide hydrochloride) 500 microgram/1 each conventional release oral capsule (clinical drug) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely anagrelide hydrochloride 1 milligram/1 each conventional release oral capsule Plays role False Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing anagrelide in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Anagrelide Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Vemurafenib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing only vemurafenib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing vemurafenib Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing precisely vemurafenib 240 milligram/1 each conventional release oral capsule Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing vemurafenib in oral dose form (medicinal product form) Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier
Product containing asparaginase Plays role True Antineoplastic therapeutic role Inferred relationship Existential restriction modifier

Start Previous Page 6 of 26 Next End

This concept is not in any reference sets

Back to Start